Palvella Therapeutics, Inc.
Ticker: PVLA
| Insider | Title |
|---|---|
| Ahmed Mousa | Chief Business Officer |
| Ann Barbier | Director |
| Capital Management, Llc Adar1 | 10% or greater ownership |
| Christopher P Kiritsy | Director |
| Gp Holdings Llc Bvf | 10% or greater ownership |
| Hitto Kaufmann | SVP, Chief Scientific Officer |
| I Gp Llc Bvf | 10% or greater ownership |
| Ii Gp Llc Bvf | See Explanation of Responses |
| Inc/il Bvf | 10% or greater ownership |
| Investments Lp Dellora | 10% or greater ownership |
| James A Geraghty | Director |
| Mark N Lampert | 10% or greater ownership |
| Matthew L Sherman | Director |
| Maya R. Said | Director |
| Michael Richman | Director |
| Partners L P/il Bvf | 10% or greater ownership |
| Partners Os Ltd. Bvf | See Explanation of Responses |
| Partners, Lp Adar1 | 10% or greater ownership |
| Peter A Kiener | Director |
| Shane Olwill | Chief Development Officer |
| Stephen S. Yoder | Chief Executive Officer, Director |
| Thomas Bures | Chief Financial Officer |
| Tim Demuth | Chief Medical Officer |
| Value Fund Ii Lp Biotechnology | See Explanation of Responses |
| Value Fund L P Biotechnology | 10% or greater ownership |
| Value Trading Fund Os Lp Biotechnology | See Explanation of Responses |